Venetoclax and Azacitidine for Therapy-Related MDS

Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
53 patients (estimated)
Sponsors
Ohio State University Comprehensive Cancer Center
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1481
NCT Identifier
NCT05379166

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.